The global relapsed or refractory diffuse large B-cell lymphoma market size was valued at USD 1,500 million in 2021 and is projected to reach around USD 2,200 million in 2030 exhibiting a CAGR of 4.2% in the forecasted period.
The market demand is being driven by rising prevalence rates of atopic dermatitis and other skin disorders. Additionally, rising product adoption rates worldwide are being attributed to greater awareness of available treatment options. Demand will eventually rise as a result of the ageing population and the high incidence rates of pruritus in this subset. Additionally, an increase in tourist activities like hiking and camping may expose people to insects or irritating substances that set off a reaction that causes itching in sensitive skin areas, which would increase demand for the product globally over the coming years. It is anticipated that the existence of growing economies, exemplified by nations like China and India, will create new economic opportunities.
The rise in incidence of atopic dermatitis and other skin disorders is boosting demand. Global product uptake rates are also rising as more people become aware of available treatment options. Over time, demand will rise due to the ageing population’s higher than average incidence of pruritus and other factors. Furthermore, a rise in tourist activities like hiking and camping may expose people to insects or irritating substances that set off a reaction that causes itching on sensitive skin areas, inflicting discomfort on people and increasing sales globally over the ensuing years.
Click Here, Download a Free Sample Copy of this Market: https://wemarketresearch.com/sample-request/relapsed-or-refractory-diffuse-large-b-cell-lymphoma-market/904/
Key Companies Insights
The market for relapsed or refractory diffuse large B-cell lymphoma is moderately competitive. With the rising applications of Relapsed or refractory diffuse large B-cell lymphoma, new players are considering to enter the market. The companies are also involved in events like joint ventures, acquisitions, partnerships, mergers, and collaborations. These activities aid in growing the effect of the players in the Relapsed or refractory diffuse large B-cell lymphoma, ultimately boosting the market growth. Some of the key companies working in the global Relapsed or refractory diffuse large B-cell lymphoma include:
• Karyopharm Therapeutics
• Merck & Co., Inc.
• MorphoSys, Inc.
• Novartis AG
• Bristol Myers Squibb
• Gilead Sciences, Inc.
• F. Hoffmann-La Roche AG
• Other players
Some of the Recent Developments:
• In November 2020, Xencor, MorphoSys and Incyte entered into a clinical collaboration to examine the combination of tafasitamab, enalidomide, and plamotamab in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
• In July 2020, MorphoSys AG and Incyte got approval from the U.S. Food and Drug Administration (FDA) for Monjuvi along with lenalidomide for the management of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL rising from low grade lymphoma, and who are not entitled for autologous stem cell transplant (ASCT).
Segments
By Drug Class
• Monjuvi
• XPOVIO
• Polivy
• Kymriah
• Yescarta
• Others
By Distribution Channel
• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies
By Geography
• North America
o U.S.
o Canada
o Mexico
• Europe
o U.K.
o Germany
o France
o Italy
o Spain
o Russia
• Asia-Pacific
o Japan
o China
o India
o Australia
o South Korea
o ASEAN
• Latin America
o Brazil
o Argentina
o Colombia
• MEA
o South Africa
o Saudi Arabia
o UAE
o Egypt
Get A Report Copy of this Market: https://wemarketresearch.com/reports/relapsed-or-refractory-diffuse-large-b-cell-lymphoma-market/904/
Additionally, rise in focus of manufacturers on adoption of inorganic growth strategies such as partnerships and acquisitions, to strengthen their product portfolio, and increase in rate of research activities by market players to develop treatment for relapsed or refractory diffuse large B-cell lymphoma quicken the market growth. Conversely, high cost related to the treatment and identification of relapsed or refractory diffuse large b-cell lymphoma is projected to hinder the market growth. Lack of skilled professionals is expected to challenge the Market in the forecasted period.
Key Questions Answered:
1. What is the market size and CAGR of the Market during the forecast period?
2. How is the growing demand impacting the growth of Market shares?
3. What is the growing demand of the Market during the forecast period?
4. Who are the leading vendors in the market and what are their market shares?
5. What is the impact of the COVID-19 pandemic on the APAC Market?
